Neuroendocrine Prostate Cancer Market to Grow 25% Annually Through 2036
The neuroendocrine prostate cancer market is projected to grow at a 25% CAGR by 2036, driven by emerging therapies and increased disease awareness. The market was valued at $5 million in 2025.
The market for neuroendocrine prostate cancer (NEPC) treatments is forecast to expand significantly, with an anticipated compound annual growth rate of 25% through 2036. Analysts attribute this projected growth to the emergence of novel therapeutic agents, including DLL3-targeted therapies, antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), CAR-T cell therapies, aurora kinase inhibitors, and EZH2 inhibitors.
The NEPC market, valued at an estimated $5 million across seven major markets in 2025, is benefiting from improved diagnostics and a growing pipeline of clinical trials. The United States currently represents the largest share of the NEPC treatment market, with the EU4 countries, the United Kingdom, and Japan also showing growth potential.
Increased recognition of NEPC as an aggressive and treatment-resistant form of prostate cancer is fueling the development of new treatment strategies. Several promising therapies are currently in clinical trials, such as Peluntamig (PT217) by Phanes Therapeutics and Tarlatamab (AMG 757) by Amgen, which target DLL3-expressing tumors.
Major pharmaceutical companies, including Amgen, Merck Sharp & Dohme, and Bristol-Myers Squibb, are investing in NEPC research. Tarlatamab is expected to see rapid market uptake following regulatory approval, addressing a significant unmet medical need with its novel mechanism of action.